多西他赛联合表柔比星在局部晚期乳腺癌新辅助化疗中的疗效  

Combination of docetaxel and epirubicin in the Neoadjuvoant chemotherapy of locally advanced breast cancer

作　　者：陈登峰[1] 

机构地区：[1]华中科技大学同济医学院附属荆州医院乳腺科,434020

出　　处：《中国保健营养（临床医学学刊）》2010年第4期43-45,共3页China Health Care Nutrtion

摘　　要：目的观察多西他赛联合表柔比星在局部晚期乳腺癌新辅助化疗中的疗效和毒性反应。方法42例局部晚期乳腺癌患者接受多西他赛75mg／m^2，静脉滴入d1；表柔比星90mg／m^2，静脉滴入，d1。每21天为一周期，共行2-4个周期化疗后再行局部治疗。结果总临床客观缓解率（CR＋PR）88．1％。主要不良反应是白细胞下降，Ⅲ度及Ⅳ度白细胞减少达54．8％。结论多西他赛联合表柔比星的新辅助化疗方案，有较好的客观缓解率，毒副反应可以耐受，对局部晚期乳腺癌患者而言是一个很好的新辅助化疗方案。Objective ： To evaluate the efficacy and toxicity of docetaxel plus epirubicin in the Neoadjuvoant chemotherapy of locally advanced breast cancer （LABC） . Methods： Forty-second patients with LABC were treated with docetaxel 75 mg/m^2 dl epirubicin 90 mg/m^3, d1. Each cycle was 3 weeks.All patients finished 2 to 4 cycles before local treatmeat .Results： The CR＋PR rate was 88.1%.Main toxicity was neutropenia. Grade Ⅲ, Ⅳ neutropenia were 54.8%. Conclusions： The Combination of docetaxel and epirubicin is well tolerated and is effective in the Neoadjuvoant chemotherapy of locally advanced breast cancer.

关 键 词：乳腺肿瘤 新辅助化疗 多西他赛 表柔比星 

分 类 号：R737.9[医药卫生—肿瘤]